EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comprehensive Proteomic Analysis of Dysferlinopathy Unveiling Molecular Mechanisms and Biomarkers Linked to Pathological Progression

Di Wang iD, Xin-Yi Liu, Qi-Fang He, Fu-Ze Zheng, Long Chen, Ying Zheng, Ming-Hui Zeng, Yu-Hua Lin, Xin Lin, Hai-Zhu Chen, Min-Ting Lin, Ning Wang und 2 weitere

CNS Neuroscience & Therapeutics · 2024

DOI: 10.1111/cns.70065 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2024. Verfasst von Di Wang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Pathology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China. Hauptthemen laut MEDLINE: Proteomics, Muscular Dystrophies, Limb-Girdle, Muscle, Skeletal, Biomarkers. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Fujian Province, National Natural Science Foundation of China, The Joint Funds for the Innovation of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Previous proteomics studies in dysferlinopathy muscle have been limited in scope, often utilizing 2D‐electrophoresis and yielding only a small number of differential expression calls. To address this gap, this study aimed to employ high‐resolution proteomics to explore the proteomic landscapes of dysferlinopathy and analyze the correlation between muscle pathological changes and alterations in protein expression in muscle biopsies.

Methods

We conducted a comprehensive approach to investigate the proteomic profile and disease‐associated changes in the muscle tissue proteome from 15 patients with dysferlinopathy, exhibiting varying degrees of dystrophic pathology, alongside age‐matched controls. Our methodology encompasses tandem mass tag (TMT)‐labeled liquid chromatography‐mass spectrometry (LC–MS/MS)‐based proteomics, protein–protein interaction (PPI) network analysis, weighted gene co‐expression network analysis, and differential expression analysis. Subsequently, we examined the correlation between the expression of key proteins and the clinical characteristics of the patients to identify pathogenic targets associated with DYSF mutations in dysferlinopathy.

Results

A total of 1600 differentially expressed proteins were identified, with 1321 showing high expression levels and 279 expressed at lower levels. Our investigation yields a molecular profile delineating the altered protein networks in dysferlinopathy‐afflicted skeletal muscle, uncovering dysregulation across numerous cellular pathways and molecular processes, including mRNA metabolic processes, regulated exocytosis, immune response, muscle system processes, energy metabolic processes, and calcium transmembrane transport. Moreover, we observe significant associations between the protein expression of ANXA1, ANXA2, ANXA4, ANXA5, LMNA, PYGM, and the extent of histopathologic changes in muscle biopsies from patients with dysferlinopathy, validated through immunoblotting and immunofluorescence assays.

Conclusions

Through the aggregation of expression data from dysferlinopathy‐impacted muscles exhibiting a range of pathological alterations, we identified multiple key proteins associated with the dystrophic pathology of patients with dysferlinopathy. These findings provide novel insights into the pathogenesis of dysferlinopathy and propose promising targets for future therapeutic endeavors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProteomicsMuscular Dystrophies, Limb-GirdleMuscle, SkeletalBiomarkersDisease ProgressionHumansMaleFemaleAdultYoung AdultAdolescentChildDysferlinMiddle AgedChild, PreschoolProtein Interaction MapsMuscle ProteinsTandem Mass Spectrometry

Stichwörter der Autor:innen

annexinsdysferlinopathyinflammationpathological progressionpotential biomarkersproteomicstherapeutic targets

Substanzen

BiomarkersDYSF protein, humanDysferlinMuscle Proteins

Autor:innen und Institutionen

  • Department of Molecular Pathology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
  • Center for Bioinformatics, National Infrastructures for Translational Medicine, Institute of Clinical Medicine and Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical Coll…
  • Department of Neurology and Institute of Neurology of First Affiliated Hospital, Institute of Neuroscience, and Fujian Key Laboratory of Molecular Neurology, Fujian Medical University, Fuzhou, China.
  • Department of Neurology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.

ORCID-Profile: Di Wang, Feng Lin

Förderung

  • Natural Science Foundation of Fujian Province
  • National Natural Science Foundation of China
  • The Joint Funds for the Innovation of Science and Technology

Zitieren

APA

Wang, D., Liu, X. Y., He, Q. F., Zheng, F. Z., Chen, L., Zheng, Y., Zeng, M. H., Lin, Y. H., Lin, X., Chen, H. Z., Lin, M. T., Wang, N., Wang, Z. Q., & Lin, F. (2024). Comprehensive Proteomic Analysis of Dysferlinopathy Unveiling Molecular Mechanisms and Biomarkers Linked to Pathological Progression. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.70065

Vancouver

Wang D, Liu XY, He QF, Zheng FZ, Chen L, Zheng Y, et al. Comprehensive Proteomic Analysis of Dysferlinopathy Unveiling Molecular Mechanisms and Biomarkers Linked to Pathological Progression. CNS Neuroscience & Therapeutics. 2024. doi:10.1111/cns.70065

BibTeX
@article{Wang2024,
  author = {Wang, Di and Liu, Xin-Yi and He, Qi-Fang and Zheng, Fu-Ze and Chen, Long and Zheng, Ying and Zeng, Ming-Hui and Lin, Yu-Hua and Lin, Xin and Chen, Hai-Zhu and Lin, Min-Ting and Wang, Ning and Wang, Zhi-Qiang and Lin, Feng},
  title = {Comprehensive Proteomic Analysis of Dysferlinopathy Unveiling Molecular Mechanisms and Biomarkers Linked to Pathological Progression},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2024},
  doi = {10.1111/cns.70065}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche